Challenges to curing primary brain tumours
By Kenneth D. Aldape, K. Brindle, L. Chesler, R. Chopra, A. Gajjar, M. Gilbert, N. Gottardo, D. Gutmann, D. Hargrave, Eric C. Holland and 16 more. Nature Reviews Clinical Oncology, 2019
771 citations recorded by the source corpus.
Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment.Brain cancer encompasses a diverse range of complex malignancies, many of which are associated with a poor prognosis and require more effective treatments. In this Position Paper, an international panel of clinicians and laboratory-based scientists convened by Cancer Research UK identify and discuss seven challenges that must be overcome if we are to cure all patients with a brain tumour.
Subfields: Cell Biology, Developmental Neuroscience, Genetics
View Paper: https://www.semanticscholar.org/paper/cd4c22b87ef55963786f1224fdf08459096f64fe
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
In Developmental Neuroscience
In Genetics
Citations in the corpus
- Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients (2021, background): “Glioma recurrence or malignant progression occurs likely for several reasons: (1) infiltrative tumor cells cannot be completely removed by neurosurgical resection [9,10]; (2) residual tumor cells cannot be effectively suppressed by limited postoperative treatment options [3,11,12]; (3) multiple lesi”
- Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells (2020, background): “, 2005), median survival rates for glioblastoma patients remain stubbornly low (Aldape et al., 2019).”